The move, it said, is in response to increased customer requirements for such high growth fill formats, with Marc Funk, CEO, Recipharm, noting that the growing demand for pre-filled syringes is projected to translate into a market value of US$6.5bn by 2030.
As part of a program of recent investments and expansions across the wider business, the CDMO said this investment will further enhance its comprehensive manufacturing offering for injectable products that require sterile filling.
The Wasserburg site specializes in more complex formats ranging from lyophilization technology and aseptic filling into vials, syringes, and cartridges.
The new line can support small volume projects as well as large ones and is expected to be ready for technical trials by April 2023 with the first GMP batch to run in May next year.
Recipharm, which has around 9,000 employees, operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US.
It is also investing in new fill/finish facilities in France, Italy, India, and Morocco.
Biologics strategy
The Swedish company, in its strategy to provide innovative drug developers in the biologics market with scientifically differentiated contract development and manufacturing services, was on the asset trail at the start of this year.
February 2022 saw it acquire Arranta Bio and Vibalogics, with the CDMO saying the deals would leave it better placed it to serve the advanced therapy medicinal products (ATMPs) market.
Arranta Bio has established a strong service portfolio, delivering microbiome therapeutic products and mRNA clinical production capabilities, while ownership of Vibalogics gives Recipharm capabilities in new biologics modalities, expertise in oncolytic viruses, viral vaccines, and viral vector gene therapies.
